Mechanistically, a study in ccRCC has described that the loss of SETD2-mediated H3K36me3 activates enhancers to drive oncogenic transcriptional output through regulation of chromatin accessibility [132]. Here, SETD2 is linked to nonpapillary renal cell carcinoma.